Age (years)
|
≤ 40
|
57 (16.7)
|
30 (8.8)
|
27 (7.9)
|
> 40
|
285 (83.3)
|
163 (47.7)
|
122 (35.7)
|
Family history of cancera
|
None
|
275 (80.4)
|
152 (44.4)
|
123 (36.0)
|
Breast cancer or ovarian cancer
|
19 (5.6)
|
8 (2.3)
|
11 (3.2)
|
Other malignancies
|
48 (14.0)
|
33 (9.6)
|
15 (4.4)
|
Menstrual station
|
Premenopause
|
218 (63.7)
|
120 (35.1)
|
98 (28.7)
|
Postmenopause
|
118 (34.5)
|
71 (20.8)
|
47 (13.7)
|
Unclear
|
6 (1.8)
|
2 (0.6)
|
4 (1.2)
|
Clinical stage
|
I + II
|
154 (45.0)
|
89 (26.0)
|
65 (19.0)
|
III
|
143 (41.8)
|
85 (24.9)
|
58 (17.0)
|
IV
|
14 (4.1)
|
5 (1.5)
|
9 (2.6)
|
Unclear
|
31 (9.1)
|
14 (4.1)
|
17 (5.0)
|
Pathological type
|
Intraductal carcinoma
|
4 (1.2)
|
2 (0.6)
|
2 (0.6)
|
Infiltrating ductal carcinoma
|
306 (89.5)
|
172 (50.3)
|
134 (39.2)
|
Invasive lobular carcinoma
|
17 (5.0)
|
11 (3.2)
|
6 (1.8)
|
Others
|
11 (3.2)
|
7 (2.0)
|
4 (1.2)
|
Unclear
|
4 (1.2)
|
1 (0.3)
|
3 (0.9)
|
Pathological grade
|
Grade 1
|
10 (2.9)
|
8 (2.3)
|
2 (0.6)
|
Grade 2–3
|
170 (49.7)
|
96 (28.1)
|
74 (21.6)
|
Unclear
|
162 (47.4)
|
89 (26.0)
|
73 (21.3)
|
Vascular invasion
|
No
|
308 (90.1)
|
174 (50.9)
|
134 (39.2)
|
Yes
|
34 (9.9)
|
19 (5.6)
|
15 (4.4)
|
Axillary lymph node metastasis at initial diagnosis
|
No
|
106 (31.0)
|
54 (15.8)
|
52 (15.2)
|
Yes
|
225 (65.8)
|
136 (39.8)
|
89 (26.0)
|
Unclear
|
11 (3.2)
|
3 (0.9)
|
8 (2.3)
|
Distant metastasis at initial diagnosis
|
No
|
324 (94.7)
|
186 (54.4)
|
138 (40.4)
|
Yes
|
14 (4.1)
|
5 (1.5)
|
9 (2.6)
|
Unclear
|
4 (1.2)
|
2 (0.6)
|
2 (0.6)
|
ER status
|
Positive
|
215 (62.9)
|
123 (36.0)
|
92 (26.9)
|
Negative
|
117 (34.2)
|
65 (19.0)
|
52 (15.2)
|
Unclear
|
10 (2.9)
|
5 (1.5)
|
5 (1.5)
|
PR status
|
Positive
|
213 (62.3)
|
117 (34.2)
|
96 (28.1)
|
Negative
|
118 (34.5)
|
70 (20.5)
|
48 (14.0)
|
Unclear
|
11 (3.2)
|
6 (1.8)
|
5 (1.5)
|
HER2 status
|
Positive
|
83 (24.3)
|
47 (13.7)
|
36 (10.5)
|
Negative
|
230 (67.3)
|
130 (38.0)
|
100 (29.2)
|
Unclearb
|
29 (8.5)
|
16 (4.7)
|
13 (3.8)
|
Therapy
|
Capecitabine
|
20 (5.8)
|
10 (2.9)
|
10 (2.9)
|
Docetaxel plus capecitabine
|
205 (59.9)
|
123 (36.0)
|
82 (24.0)
|
Vinorelbine plus capecitabine
|
98 (28.7)
|
48 (14.0)
|
50 (14.6)
|
Othersc
|
19 (5.6)
|
12 (3.5)
|
7 (2.0)
|
Therapy line
|
First-line
|
211 (61.7)
|
121 (35.4)
|
90 (26.3)
|
Multi-line
|
131 (38.3)
|
72 (21.1)
|
59 (17.3)
|
Metastatic site
|
No visceral metastasis (including local recurrence)
|
104 (30.4)
|
60 (17.5)
|
44 (12.9)
|
Visceral metastasis
|
238 (69.6)
|
133 (38.9)
|
105 (30.7)
|
Maintenance therapy
|
Yes
|
137 (40.1)
|
94 (27.5)
|
43 (12.6)
|
No
|
205 (59.9)
|
99 (28.9)
|
106 (31.0)
|
Response evaluation
|
CR
|
7 (2.0)
|
5 (1.5)
|
2 (0.6)
|
PR
|
194 (56.7)
|
107 (31.3)
|
87 (25.4)
|
SD
|
90 (26.3)
|
56 (16.4)
|
34 (9.9)
|
PD
|
39 (11.4)
|
20 (5.8)
|
19 (5.6)
|
Unclear
|
12 (3.5)
|
5 (1.5)
|
7 (2.0)
|
Survival conditiond
|
Alive
|
218 (63.7)
|
124 (36.3)
|
94 (27.5)
|
Dead
|
124 (36.3)
|
69 (20.2)
|
55 (16.1)
|